

Streamline Health® Reports Fourth Quarter And Fiscal Year 2015 Financial Performance

Fourth Quarter Revenues \$6.4 Million; \$9.9 Million Cash on Hand; FY 2015 Revenues \$28.3 Million; \$5.9 Million in Cash from Operations; 2015 Adjusted EBITDA \$2.8 Million; \$5.6 million Net Loss

ATLANTA, April 20, 2016 /PRNewswire/ -- Streamline Health Solutions, Inc. (NASDAQ: STRM), provider of the Looking Glass® platform of integrated solutions and analytics supporting revenue cycle optimization for healthcare enterprises in the new value-based world, today announced financial results for the fourth quarter and fiscal year of 2015, which ended January 31, 2016.



Revenue for the three-month period ended January 31, 2016 declined 3.4 percent to \$6.4 million as compared to the three-months ending January 31, 2015. Adjusted EBITDA for the fourth quarter was \$0.5 million, up from \$(0.7) million in the same period a year ago. Net loss for the fourth quarter was \$1.8 million, improved from a \$5.1 million net loss in the same period a year ago.

Revenues for fiscal year 2015 were \$28.3 million, up 2.5% from \$27.6 million the previous fiscal year. Recurring revenues for the year constituted 85% of overall revenue, or \$24.1 million. Adjusted EBITDA for the fiscal year was \$2.8 million, up from (\$1.0) million in fiscal year 2014.

"2015 was a year of significant improvement over 2014 in terms of our balance sheet and operational efficiency," stated David Sides, President and Chief Executive Officer, Streamline Health. "Cash from operations improved year over year by nearly \$9 million from (\$3.0) million to \$5.9 million. We increased our total cash on hand by \$3.4 million and reduced our term loans by \$1.5 million. In addition, we improved Adjusted EBITDA by \$3.8 million year over year.

We have begun investing significantly in sales and marketing to ramp up our revenue growth going forward and are rebalancing our solution development efforts from a stability emphasis to one focused on innovation that addresses our future client needs and drives higher quality for our users as our industry moves to value-based care."

Highlights for the fourth quarter and fiscal year ended January 31, 2016 included:

- Revenues for the fourth quarter 2015 were \$6.4 million, and for the year were \$28.3 million;
- Adjusted EBITDA for the fourth quarter 2015 was \$0.5 million, and for the year was \$2.8 million;
- Recorded net loss of \$(1.4) million for the three-month period ended January 31, 2016, and \$(4.3) million for the fiscal year 2015;
- New sales bookings for the quarter were \$2.0 million and \$15.3 million for the fiscal year; and
- Backlog at the end of the quarter was \$67.1 million.

Conference Call Information

The Company will conduct a conference call to review the results on Wednesday, April 20, 2016 at 5:00 PM ET. Interested parties can access the call via live webcast; <u>click here</u> to register. The call can also be accessed by dialing 888-359-3624 and then entering passcode 2145327.

A replay of the conference call will be available from Wednesday, April 20, 2016 at 8:00 PM ET to Monday, April 25, 2016 at 8:00 PM ET by dialing 888-203-1112 and entering passcode 2145327.

Streamline Health reports its financial results in accordance with U.S. generally accepted accounting principles ("GAAP"). Streamline Health's management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline Health's management believes that this measure provides useful supplemental information regarding the performance of Streamline Health's business operations.

Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table illustrating this measure is included in this press release.

About Streamline Health

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge - actionable insights that support revenue cycle optimization for healthcare enterprises. Our Looking Glass® platform delivers integrated solutions and analytics that enable providers to drive reimbursement in a value-based world. We share a common calling and commitment to advance the quality of life and the quality of healthcare - for society, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company's estimates of future revenue, backlog, results of investments in sales and marketing, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company's solutions, the ability of the Company to control costs, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, and the Company's ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Company Contact:

Randy Salisbury SVP, Chief Marketing Officer (404) 229-4242 randy.salisbury@streamlinehealth.net

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

		onth uary	s Ended 31,	_	Fiscal	Yea	r Ended
	2016	_	2015	_	2016	_	2015
Revenues:							
Systems sales	\$ 378,594	\$	215,670	\$	2,946,304	\$	1,214,879
Professional services	580,124		848,279		2,212,002		2,580,167
Maintenance and support	3,829,816		3,745,952		15,145,480		16,157,371
Software as a service	1,582,314		1,785,622	-	8,010,672	-	7,672,990

Operating expenses: Cost of systems sales 660,632 1,031,305 2,778,041 3,536,495 Cost of services 894,852 1,012,518 3,143,881 3,458,984 Cost of maintenance and support 738,778 534,662 3,036,550 3,087,842 Cost of software as a service 389,385 807,013 2,442,143 2,920,403 Selling, general and administrative 2,806,429 3,299,977 13,442,799 16,225,574 Research and development 2,377,712 2,905,233 9,093,353 9,756,206 Impairment of intangible assets	Total revenues		6,370,848	-	6,595,523	28,314,458	27,625,407
Cost of services 894,852 1,012,518 3,143,881 3,458,984 Cost of maintenance and support 738,778 534,662 3,036,550 3,087,842 Cost of software as a service 389,385 807,013 2,442,143 2,920,403 Selling, general and administrative 2,806,429 3,299,977 13,442,799 16,225,574 Research and development 2,377,712 2,905,233 9,093,353 9,756,206 Impairment of intangible assets	Operating expenses:						
Cost of maintenance and support 738,778 534,662 3,036,550 3,087,842 Cost of software as a service 389,385 807,013 2,442,143 2,920,403 Selling, general and administrative 2,806,429 3,299,977 13,442,799 16,225,574 Research and development 2,377,712 2,905,233 9,093,353 9,756,206 Impairment of intangible assets 1,952,000 1,952,000 Total operating expenses 7,867,788 11,542,708 33,936,767 40,937,504 Operating loss (1,496,940) (4,947,185) (5,622,309) (13,312,097) Other income (expense): (185,824) (225,370) (884,226) (748,969) Loss on early extinguishment of debt (315,327) (429,849) Miscellaneous income (expenses) 284,880 (211,060) 2,224,423 1,592,449 Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 <	Cost of systems sales		660,632		1,031,305	2,778,041	3,536,495
Cost of software as a service 389,385 807,013 2,442,143 2,920,403 Selling, general and administrative 2,806,429 3,299,977 13,442,799 16,225,574 Research and development 2,377,712 2,905,233 9,093,353 9,756,206 Impairment of intangible assets 1,952,000 1,952,000 Total operating expenses 7,867,788 11,542,708 33,936,767 40,937,504 Operating loss (1,496,940) (4,947,185) (5,622,309) (13,312,097) Other income (expenses): (185,824) (225,370) (884,226) (748,969) Loss on early extinguishment of debt (315,327) (429,849) Miscellaneous income (expenses) 284,880 (211,060) 2,224,423 1,592,449 Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (1,038,310) <tr< td=""><td>Cost of services</td><td></td><td>894,852</td><td></td><td>1,012,518</td><td>3,143,881</td><td>3,458,984</td></tr<>	Cost of services		894,852		1,012,518	3,143,881	3,458,984
Selling, general and administrative 2,806,429 3,299,977 13,442,799 16,225,574 Research and development 2,377,712 2,905,233 9,093,353 9,756,206 Impairment of intangible assets 1,952,000 1,952,000 Total operating expenses 7,867,788 11,542,708 33,936,767 40,937,504 Operating loss (1,496,940) (4,947,185) (5,622,309) (13,312,097) Other income (expense): (185,824) (225,370) (884,226) (748,969) Loss on early extinguishment of debt (315,327) (429,849) Miscellaneous income (expenses) 284,880 (211,060) 2,224,423 1,592,449 Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (1,2011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,0	Cost of maintenance and support		738,778		534,662	3,036,550	3,087,842
Research and development 2,377,712 2,905,233 9,093,353 9,756,206 Impairment of intangible assets	Cost of software as a service		389,385		807,013	2,442,143	2,920,403
Impairment of intangible assets	Selling, general and administrative		2,806,429		3,299,977	13,442,799	16,225,574
Total operating expenses 7,867,788 11,542,708 33,936,767 40,937,504 Operating loss (1,496,940) (4,947,185) (5,622,309) (13,312,097) Other income (expense): Interest expense (185,824) (225,370) (884,226) (748,969) Loss on early extinguishment of debt	Research and development		2,377,712		2,905,233	9,093,353	9,756,206
Operating loss (1,496,940) (4,947,185) (5,622,309) (13,312,097) Other income (expense): Interest expense (185,824) (225,370) (884,226) (748,969) Loss on early extinguishment of debt (315,327) (429,849) Miscellaneous income (expenses) 284,880 (211,060) 2,224,423 1,592,449 Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (12,011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders (1,772,300) (5,096,452) (5,626,187) (13,049,767) Basic net loss per common share (0.09) (0.28) (0.30) (0.71) Number of shares used in basic per common share computation 18,689,854 18,417,100 18,689,854 18,261,800 Diluted net loss per common share <td>Impairment of intangible assets</td> <td></td> <td></td> <td></td> <td>1,952,000</td> <td></td> <td>1,952,000</td>	Impairment of intangible assets				1,952,000		1,952,000
Other income (expense): Interest expense (185,824) (225,370) (884,226) (748,969) Loss on early extinguishment of debt (315,327) (429,849) Miscellaneous income (expenses) 284,880 (211,060) 2,224,423 1,592,449 Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (12,011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders (1,772,300) (5,096,452) (5,626,187) (13,049,767) Basic net loss per common share (0.09) 18,417,100 18,689,854 18,261,800 Diluted net loss per common share (0.09) (0.28) (0.30) (0.71)	Total operating expenses		7,867,788		11,542,708	33,936,767	40,937,504
Interest expense (185,824) (225,370) (884,226) (748,969) Loss on early extinguishment of debt (315,327) (429,849) Miscellaneous income (expenses) 284,880 (211,060) 2,224,423 1,592,449 Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (12,011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders (1,772,300) (5,096,452) (5,626,187) (13,049,767) Basic net loss per common share (0.09) (0.28) (0.30) (0.71) Number of shares used in basic per common share computation 18,689,854 18,417,100 18,689,854 18,261,800 Diluted net loss per common share (0.09) (0.028) (0.30) (0.71)	Operating loss		(1,496,940)		(4,947,185)	(5,622,309)	(13,312,097)
Loss on early extinguishment of debt (315,327) (429,849) Miscellaneous income (expenses) 284,880 (211,060) 2,224,423 1,592,449 Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (12,011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders (1,772,300) (5,096,452) (5,626,187) (13,049,767) Basic net loss per common share (0.09) (0.28) (0.30) (0.71) Number of shares used in basic per common share computation 18,689,854 18,417,100 18,689,854 18,261,800 Diluted net loss per common share (0.09) (0.28) (0.30) (0.71)	Other income (expense):						
Miscellaneous income (expenses) 284,880 (211,060) 2,224,423 1,592,449 Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (12,011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders (1,772,300) (5,096,452) (5,626,187) (13,049,767) Basic net loss per common share (0.09) 18,417,100 18,689,854 18,261,800 Diluted net loss per common share (0.09) (0.28) (0.30) (0.30) (0.71)	Interest expense		(185,824)		(225,370)	(884,226)	(748,969)
Loss before income taxes (1,397,884) (5,698,942) (4,282,112) (12,898,466) Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (12,011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders (1,772,300) (5,096,452) (5,626,187) (13,049,767) Basic net loss per common share (0.09) (0.28) (0.30) (0.71) Number of shares used in basic per common share (0.09) (0.28) (0.30) (0.30) Diluted net loss per common share (0.09) (0.28) (0.30) (0.30)	Loss on early extinguishment of debt				(315,327)		(429,849)
Income tax (expense) benefit (5,358) 889,299 (8,003) 887,009 Net loss (1,403,242) (4,809,643) (4,290,115) (12,011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders (1,772,300) (5,096,452) (5,626,187) (13,049,767) Basic net loss per common share (0.09) (0.28) (0.30) (0.71) Number of shares used in basic per common share (0.09) (0.28) (0.30) (0.30) Diluted net loss per common share (0.09) (0.28) (0.30) (0.71)	Miscellaneous income (expenses)		284,880		(211,060)	2,224,423	1,592,449
Net loss \$ (1,403,242) \$ (4,809,643) \$ (4,290,115) \$ (12,011,457) Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders \$ (1,772,300) \$ (5,096,452) \$ (5,626,187) \$ (13,049,767) Basic net loss per common share \$ (0.09) \$ (0.28) \$ (0.30) \$ (0.71) Number of shares used in basic per common share \$ (0.28) \$ (0.28) \$ (0.30) \$ (0.30) \$ (0.70) Diluted net loss per common share \$ (0.28) \$ (0.28) \$ (0.30)	Loss before income taxes		(1,397,884)		(5,698,942)	(4,282,112)	(12,898,466)
Less: deemed dividends on Series A Preferred Shares (369,058) (286,809) (1,336,072) (1,038,310) Net loss attributable to common shareholders \$ (1,772,300) \$ (5,096,452) \$ (5,626,187) \$ (13,049,767) Basic net loss per common share \$ (0.09) \$ (0.28) \$ (0.30) \$ (0.71) Number of shares used in basic per common share \$ (0.09) \$ (0.28) \$ (0.30) \$ (0.30) Diluted net loss per common share \$ (0.09) \$ (0.28) \$ (0.30) \$ (0.71)	Income tax (expense) benefit		(5,358)		889,299	(8,003)	887,009
Net loss attributable to common shareholders \$ (1,772,300) \$ (5,096,452) \$ (5,626,187) \$ (13,049,767) Basic net loss per common share \$ (0.09) \$ (0.28) \$ (0.30) \$ (0.71) Number of shares used in basic per common share computation 18,689,854 18,417,100 18,689,854 18,261,800 Diluted net loss per common share \$ (0.09) \$ (0.28) \$ (0.30) \$ (0.30) \$ (0.71)	Net loss	\$	(1,403,242)	\$	(4,809,643)	\$ (4,290,115)	\$ (12,011,457)
Basic net loss per common share \$ \(\begin{array}{c ccccccccccccccccccccccccccccccccccc	Less: deemed dividends on Series A Preferred Shares		(369,058)		(286,809)	(1,336,072)	(1,038,310)
Number of shares used in basic per common share computation Diluted net loss per common share \$\begin{array}{c ccccccccccccccccccccccccccccccccccc	Net loss attributable to common shareholders	\$	(1,772,300)	\$	(5,096,452)	\$ (5,626,187)	\$ (13,049,767)
Diluted net loss per common share \$ \(\begin{array}{c} \((0.09)\\ \) \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	Basic net loss per common share	\$	(0.09)	\$	(0.28)	\$ (0.30)	\$ (0.71)
The state of the s	Number of shares used in basic per common share computation		18,689,854		18,417,100	18,689,854	18,261,800
Number of shares used in diluted per common share computation 18,689,854 18,417,100 18,689,854 18,261,800	Diluted net loss per common share	\$	(0.09)	\$	(0.28)	\$ (0.30)	\$ (0.71)
	Number of shares used in diluted per common share computation	·	18,689,854		18,417,100	18,689,854	18,261,800

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

Assets

	Jar	nuary	31,
	2016	_	2015
Current assets:			
Cash and cash equivalents	\$ 9,882,136	\$	6,522,600
Accounts receivable, net of allowance for doubtful			
accounts of \$155,407 and \$665,962, respectively	4,199,315		6,935,270
Contract receivables	119,697		191,465
Prepaid hardware and third party software for			
future delivery	5,858		55,173
Prepaid client maintenance contracts	956,913		935,858
Other prepaid assets	941,532		1,437,680
Deferred income taxes			220,004
Other current assets	97,986	_	207,673
Total current assets	16,203,437	_	16,505,723
Non-current assets:			
Property and equipment:			
Computer equipment	2,647,135		2,381,923
Computer software	801,895		964,857
Office furniture, fixtures and equipment	683,443		683,443
Leasehold improvements	729,348	_	724,015
	4,861,821		4,754,238
Accumulated depreciation and amortization	(2,407,746)	_	(1,617,423)
Property and equipment, net	2,454,075	_	3,136,815
Contract receivables, less current portion	8,711		43,553
Capitalized software development costs, net of			
accumulated amortization of \$14,919,948 and			
\$11,846,468 respectively	6,123,638		9,197,118
Intangible assets, net of accumulated amortization			

of \$84,531 and \$13,677, respectively	8,155,325		9,500,317
Deferred financing costs	270,147		387,199
Goodwill	16,184,667		16,184,667
Other	746,018	_	823,723
Total non-current assets	33,942,581	_	39,273,392
	\$ 50,146,018	\$	55,779,115

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

Liabilities and Stockholders' Equity

	Jan	uary	31,
	2016		2015
Current liabilities:		-	
Accounts payable	\$ 1,136,779	\$	2,298,851
Accrued compensation	935,324		865,865
Accrued other expenses	328,551		563,838
Current portion of long-term debt	673,807		500,000
Deferred revenues	10,447,280		9,289,076
Current portion of capital lease obligation	592,642	_	781,961
Total current liabilities	14,114,383	-	14,299,591
Non-current liabilities:			
Term loans	7,861,084		9,500,000
Warrants liability	205,113		1,834,380
Royalty liability	2,291,888		2,385,826
Lease incentive liability, less current portion	369,406		342,129
Capital lease obligation	93,257		582,911
Deferred revenues, less current portion	1,212,709		964,933
Deferred income tax liability, less current portion			229,579
Total non-current liabilities	12,033,457	•	15,839,758
Total liabilities	26,147,840		30,139,349
Series A 0% Convertible Redeemable Preferred stock, \$.01 par value per share, \$8,849,985 redemption value, 4,000,000 shares authorized, 2,949,995 issued and outstanding, net of unamortized preferred stock discount of \$875,935 and \$2,212,007, respectively	7,974,050		6,637,978
Stockholders' equity: Common stock, \$.01 par value per share, 45,000,000 shares authorized, 18,783,540 and 18,553,389 shares issued and			
outstanding, respectively	187,836		185,534
Additional paid in capital	79,700,577		78,390,424
Accumulated deficit	(63,864,285)		(59,574,170)
Total stockholders' equity	16,024,128		19,001,788
	\$ 50,146,018	\$	55,779,115

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Fis	scal	Year
	2015	_	2014
Operating activities:			
Net loss	\$ (4,290,115)	\$	(12,011,457)
Adjustments to reconcile net loss to net cash provided by (used in)			
operating activities:			
Depreciation	1,245,400		1,005,283

Amortization of capitalized software development costs		3,073,479	3,677,991
Amortization of intangible assets		1,344,992	1,396,317
Amortization of other deferred costs		206,881	189,107
Amortization of debt discounts			47,552
Valuation adjustment for warrants liability		(1,629,267)	(2,283,345)
Deferred tax expense (benefit)		(9,575)	(720,582)
Other valuation adjustments		(39,299)	128,855
Gain from early extinguishment of lease liability		(33,059)	
Loss on impairment of intangible assets			1,952,000
Loss from early extinguishment of debt			315,327
Loss on disposal of fixed assets		92,448	180,793
Loss on exit of operating lease			234,823
Share-based compensation expense		2,386,490	1,934,298
Provision for accounts receivable		124,235	440,771
Changes in assets and liabilities, net of assets acquired:			
Accounts and contract receivables		2,718,330	2,157,977
Other assets		575,774	(637,348)
Accounts payable		(1,117,986)	600,263
Accrued expenses		(174,133)	(1,422,571)
Deferred revenues		1,405,980	(197,698)
Net cash provided by (used in) operating activities		5,880,575	(3,011,644)
Investing activities:			
Purchases of property and equipment		(518,254	(2,125,240)
Capitalization of software development costs			(619,752)
Payment for acquisition, net of cash acquired			(6,058,225)
Net cash used in investing activities		(518,254)	(8,803,217)
Financing activities:			
Proceeds from term loan			10,000,000
Principal repayments on term loan		(1,465,109)	(8,297,620)
Principal repayments on note payable			(900,000)
Principal payments on capital lease obligation		(815,826)	(368,386)
Payment of deferred financing costs		2,111	(573,002)
Proceeds from exercise of stock options and stock purchase plan		276,039	551,583
Net cash provided by (used in) financing activities		(2,002,785)	412,575
Increase (decrease) in cash and cash equivalents		3,359,536	(11,402,286)
Cash and cash equivalents at beginning of year		6,522,600	17,924,886
Cash and cash equivalents at end of year	\$	9,882,136	\$ 6,522,600
	-	·	·

STREAMLINE HEALTH SOLUTIONS, INC. Backlog (Unaudited) Table A

	January 31, 2016	October 31, 2015	January 31, 2015
Streamline Health Software Licenses	\$ 21,586,000	\$ 21,533,000	\$ 20,888,000
Hardware and Third Party Software	200,000	200,000	244,000
Professional Services	5,803,000	5,951,000	7,485,000
Maintenance and Support	23,292,000	21,057,000	21,304,000
Software as a Service	16,264,000	18,738,000	22,574,000
Total	\$ 67,145,000	\$ 67,479,000	\$ 72,495,000

STREAMLINE HEALTH SOLUTIONS, INC. New Bookings (Unaudited) Table B

Fiscal Year Ended January 31, 2016

	Value	Total Bookings
Streamline Health Software licenses	\$ 7,153,000	47%
Software as a service	2,519,000	16%
Maintenance and support	1,318,000	9%
Professional services	4,262,000	28%
Hardware & third party software	41,000	0%
Total bookings	\$ 15,293,000	100%

Reconciliation of Non-GAAP Financial Measures (Unaudited) Table C

This press release contains a non-GAAP financial measure under the rules of the U.S. Securities and Exchange Commission for adjusted EBITDA. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by generally accepted accounting principles. Non-GAAP financial measures are used internally to manage the business, such as in establishing an annual operating budget. Streamline Health's management in its operating and financial decision-making uses non-GAAP financial measures because management believes these measures reflect ongoing business in a manner that allows meaningful period-to-period comparisons. Accordingly, the Company believes it is useful for investors and others to review both GAAP and non-GAAP measures in order to (a) understand and evaluate current operating performance and future prospects in the same manner as management does and (b) compare in a consistent manner the Company's current financial results with past financial results. The primary limitations associated with the use of non-GAAP financial measures are that these measures may not be directly comparable to the amounts reported by other companies and they do not include all items of income and expense that affect operations. The Company's management compensates for these limitations by considering the company's financial results and outlook as determined in accordance with GAAP and by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached to this press release. Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, professional and advisory fees, and internal direct costs incurred to complete transactions.

Reconciliation of net earnings (loss) to non-GAAP adjusted EBITDA (in thousands):

Adjusted EBITDA Reconciliation		Three Mo	onth	s Ended,	Twelve Mo			onths Ended,		
•		January 31, 2016		January 31, 2015		January 31, 2016		January 31, 2015		
Net loss	\$	(1,403)	\$	(4,809)	\$	(4,290)	\$	(12,011)		
Interest expense		186		225		884		749		
Income tax benefit		5		(889)		8		(887)		
Depreciation Amortization of capitalized software development		314		334		1,245		1,005		
costs		741		942		3,073		3,678		
Amortization of intangible assets		333		345		1,345		1,396		
Amortization of other costs	_	46		45		136		166		
EBITDA	_	222		(3,807)		2,402		(5,904)		
Share-based compensation expense		527		648		2,386		1,934		
Loss on impairment of intangibles				1,952				1,952		
Loss on early extinguishment of debt				315				430		
Loss on disposal of fixed assets				70		92		181		
Non-cash valuation adjustments to assets and liabilities Transaction related professional fees, advisory fees		(317)		52		(1,669)		(2,154)		
and										
other internal direct costs		40		6		93		182		
Associate severances and other costs relating to										
transactions or corporate restructuring				70		206		901		
Other non-recurring operating expenses	_					(750)		1,491		
Adjusted EBITDA	\$ _	472	\$	(694)	\$	2,761	\$	(987)		
Adjusted EBITDA per diluted share										
Loss per share - diluted	\$_	(0.09)	\$	(0.28)	\$	(0.30)	\$	(0.71)		

Adjusted EBITDA per adjusted diluted share ⁽¹⁾	\$ _	0.03	\$	(0.04)	\$ 0.15	\$ (0.05)
Diluted weighted average shares		18,689,854		18,417,100	18,689,854	18,261,800
Includable incremental shares — adjusted EBITDA ⁽²⁾	_		_			
Adjusted diluted shares		18,689,854		18,417,100	18,689,854	18,261,800

- (1) Adjusted EBITDA per adjusted diluted share for the Company's common stock is computed using the more dilutive of the two-class method or the if-converted method.
- (2) The number of incremental shares that would be dilutive under profit assumption, only applicable under a GAAP net loss. If GAAP profit is earned in the current period, no additional incremental shares are assumed.

Logo - http://photos.prnewswire.com/prnh/20151208/294363LOGO

To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/streamline-health-reports-fourth-quarter-and-fiscal-year-2015-financial-performance-300254964.html

SOURCE Streamline Health Solutions, Inc.

News Provided by Acquire Media